Protalix BioTherapeutics, Inc. PLX
We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. ProCellEx®, our unique, proprietary plant cell-based protein expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Our corporate strategy includes development of treatments for rare and orphan diseases. To execute on our strategy, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. We believe our treatments of interest will address both genetic and non-genetic diseases. We currently intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M | $62.9M | $54.7M | $34.2M | $21.1M | $9.2M |
| Cost of revenue | $27.0M | $24.3M | $23.0M | $19.6M | $16.3M | $10.9M | $10.9M | $9.3M | $15.2M | $8.4M |
| Gross profit | $25.8M | $29.1M | $42.5M | $28.0M | $22.0M | $52.0M | $43.8M | $24.9M | $4.0M | $801.0K |
| R&D | $19.6M | $13.0M | $17.1M | $29.3M | $29.7M | $38.2M | $44.6M | $33.3M | $32.2M | $30.4M |
| SG&A | $11.7M | $12.2M | $15.0M | $11.7M | $12.7M | $11.1M | $9.9M | $10.9M | $11.5M | $9.4M |
| Operating income | -$5.5M | $3.9M | $10.5M | -$13.0M | -$20.5M | $2.7M | -$10.7M | -$19.3M | -$34.5M | -$33.2M |
| Pre-tax income | -$5.6M | $4.2M | $8.6M | -$14.4M | -$27.6M | -$6.5M | — | — | — | — |
| Income tax | $996.0K | $1.2M | $254.0K | $530.0K | — | — | — | — | — | — |
| Net income | -$6.6M | $2.9M | $8.3M | -$14.9M | -$27.6M | -$6.5M | -$18.3M | -$26.5M | -$83.4M | -$29.4M |
| EPS, basic | -0.08 | 0.04 | 0.12 | -0.31 | -0.62 | -0.22 | -1.23 | — | — | — |
| EPS, diluted | -0.08 | 0.04 | 0.09 | -0.31 | -0.62 | -0.22 | -1.23 | -1.80 | -6.37 | -0.29 |
| Shares, diluted (wtd. avg.) | $78.5M | $81.1M | $82.4M | $48.5M | $44.1M | $29.1M | $14.8M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.7M | $19.8M | $23.6M | $17.1M | $39.0M | $18.3M | $17.8M | $37.8M | $51.2M | $63.3M |
| Receivables | $8.8M | $2.9M | $5.3M | $4.6M | $3.4M | $2.0M | $4.7M | $4.7M | $1.7M | $693.0K |
| Inventory | $25.7M | $21.2M | $19.0M | $16.8M | $18.0M | $13.1M | $8.2M | $8.6M | $7.8M | $5.2M |
| Total current assets | $66.7M | $60.1M | $69.9M | $44.9M | $61.7M | $55.7M | $32.5M | $53.0M | $62.7M | $71.9M |
| Property, plant and equipment | $4.9M | $4.6M | $5.0M | $4.6M | $5.0M | $4.8M | $5.3M | $6.4M | $7.7M | $8.7M |
| Total assets | $82.3M | $73.4M | $84.4M | $55.8M | $73.7M | $67.9M | $45.4M | $61.1M | $72.2M | $82.2M |
| Accounts payable | — | — | $19.6M | $12.3M | $16.4M | $13.9M | $11.9M | $10.3M | $9.3M | $7.5M |
| Total current liabilities | $26.5M | $25.6M | $45.5M | $32.4M | $33.2M | $86.5M | $40.2M | $25.4M | $22.8M | $66.2M |
| Total liabilities | $34.1M | $30.2M | $50.9M | $66.4M | $79.7M | $95.0M | $115.7M | $114.0M | $101.7M | $92.2M |
| Retained earnings | -$385.0M | -$378.4M | -$381.5M | -$389.9M | -$374.9M | -$347.4M | -$340.8M | -$322.6M | -$296.1M | -$212.7M |
| Total equity | $48.2M | $43.2M | $33.6M | -$10.6M | -$6.0M | -$27.0M | -$70.3M | -$52.9M | -$29.5M | -$10.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.0M | $8.7M | -$1.3M | -$25.0M | -$10.3M | -$26.1M | -$19.4M | -$7.7M | -$10.0M | -$32.1M |
| Depreciation and amortisation | $1.5M | $1.3M | $1.2M | $1.1M | $1.1M | $1.3M | $1.6M | $1.7M | $1.9M | $2.0M |
| Stock-based compensation | $2.3M | $3.3M | $3.4M | $2.1M | $2.4M | $3.1M | $835.0K | $514.0K | $337.0K | $988.0K |
| Capital expenditure | $1.6M | $1.3M | $1.1M | $628.0K | $1.5M | $655.0K | $627.0K | $686.0K | $971.0K | $849.0K |
| Investing cash flow | -$2.4M | $4.2M | -$16.7M | -$5.0M | $18.9M | -$20.0M | -$883.0K | -$591.0K | -$1.1M | -$967.0K |
| Financing cash flow | $9.3M | -$16.8M | $24.7M | $8.2M | $12.1M | $46.5M | $0 | -$4.8M | -$1.4M | $19.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-053016.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |